For adults whose depression hasn’t improved with standard medications, SPRAVATO® offers a new path forward. This FDA-approved nasal spray is used alongside an oral antidepressant to help relieve symptoms of treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal thoughts or actions. Many major insurance plans provide coverage.
SPRAVATO® contains esketamine, a form of ketamine that acts differently from traditional antidepressants. While most antidepressants target serotonin, norepinephrine, or dopamine, esketamine primarily affects the brain’s glutamate system, supporting rapid synaptic changes that help improve mood regulation. Many people feel relief within hours to days, rather than the weeks typical of standard medications.
Your provider will review your treatment history to confirm eligibility and discuss benefits, risks, and logistics. Common short-term side effects can include dizziness, sleepiness, or altered perception during the monitored period. Our team can help verify insurance benefits and review payment options.
SPRAVATO® may be an effective option for adults with treatment-resistant depression (TRD) or major depressive disorder (MDD) when standard medications and/or therapy haven’t provided enough relief. It’s generally best for people without a history of substance misuse and without major unmanaged medical conditions.
Adults who haven’t improved after two or more oral antidepressant trials may benefit from adding SPRAVATO® to their existing medication plan as part of a supervised program.
Join our online community for insights, inspiration, and support.
Pembrooke NeuroWellness Center A Division of MacKenzie Counseling & Consultation Services, Inc.
